Dynamic transcriptome analysis reveals signatures of paradoxical effect of vemurafenib on human dermal fibroblasts

BACKGROUND: Vemurafenib (PLX4032) is one of the most frequently used treatments for late-stage melanoma patients with the BRAF(V600E) mutation; however, acquired resistance to the drug poses as a major challenge. It remains to be determined whether off-target effects of vemurafenib on normal stroma...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrales, Eyleen, Levit-Zerdoun, Ella, Metzger, Patrick, Kowar, Silke, Ku, Manching, Brummer, Tilman, Boerries, Melanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686565/
https://www.ncbi.nlm.nih.gov/pubmed/34930313
http://dx.doi.org/10.1186/s12964-021-00801-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8686565/
https://www.ncbi.nlm.nih.gov/pubmed/34930313
http://dx.doi.org/10.1186/s12964-021-00801-3

Ejemplares similares